Entrectinib -Roche’s Gene-Targeting Drug Shows Promise in Child Brain Tumors


“The young boy was running out of time. His brain tumor was growing so fast that he had trouble putting words together. All standard cancer treatments had failed. Then last summer the child started taking an experimental pill that targeted a rare genetic mutation found inside his tumor. Within months, the malignant growth started to … Continue reading Entrectinib -Roche’s Gene-Targeting Drug Shows Promise in Child Brain Tumors

Announcing The ROS1ders newsletter “ROS1derings”


We’ve created a newsletter! This newsletter will become a quarterly communication tool for The ROS1ders. In this issue, Marisa Wittebort shares tips for contributing to the ROS1 tissue study, Bärbel Söhlke​ writes about ROS1 activities in Europe, Jeff Wynne details what his data base shows about ROS1 members, and Lisa Goldman offers a fundraising update. … Continue reading Announcing The ROS1ders newsletter “ROS1derings”

Advocating for ROS1


One of the founders of the ROS1ders, Janet Freeman-Daily, shares her story and why she advocates for molecular testing, clinical trials, and the positive changes she’s seen. “Given that lung cancer patients often don’t have much tumor tissue, we should make the best use of it, and running an NGS test is the best chance … Continue reading Advocating for ROS1

Crizotinib approved for ROS1 in Australia


“From 1 January the medicine Xalkori® (crizotinib) will made available through the Pharmaceutical Benefits Scheme (PBS) for lung cancer patients with a c-ROS proto-oncogene 1 (ROS1) gene rearrangement. The drug may stop or slow the growth of Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer. Without the PBS subsidy the drug … Continue reading Crizotinib approved for ROS1 in Australia

Keep Reading Please! – A blog post by Corinne


Read about Corinne’s journey living with ROS1 positive lung cancer. “I didn’t realize it, but I was rapidly declining, dying, in late January 2016.” ” Were you WOWed reading that, knowing that I’m still here and functioning well three years after that? I was pretty darned impressed with what medical research has made possible.”

Learning and the Passage of Time – A blog post by Marisa


Marisa was diagnosed with Stage IV Adenocarcinoma in October 2015 at the age of 30. Read her inspiring post about completing grad school while living with lung cancer. “On January 12th, I submitted my final assessment for grad school. Four-hundred-and-sixty-eight days following my first footsteps into the Poli Sci department at UCL. I will never … Continue reading Learning and the Passage of Time – A blog post by Marisa